Encore: Research Update From Summit Therapeutics on Ridinilazole
January 2, 2018
Hosted by Nancy C. Caralla
Join Us With Guest Dr. Richard Vickers, Ph.D., Chief Scientific Officer at Summit Therapeutics joining us to discuss their research on a new antibiotic to treat a C. difficile infection. Learn more about Ridinilazole, clinical trials and the progress being made and moving closer to getting an urgently needed new treatment available for CDI to patients.
C. diff. Spores and More
Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
“C. diff. Spores and More” is an educational program providing you with up-to-date information pertaining to C. diff. and Healthcare-Associated infections. Raising awareness through education and advocacy saves lives worldwide. Topics are of C. difficile infection (CDI) prevention, treatments, and environmental safety products along with Healthcare-Associated Infection (HAI) awareness and more. Our guests are topic experts discussing Antibiotic Resistance, Research and Development, Clinical trials, Nutrition Counseling, Microbiome, Mental health, C. diff. survivors, and so much more. Please join us every Tuesday at 10 AM Pacific Time on the VoiceAmerica Health and Wellness Channel.
Nancy C. Caralla
Nancy C. Caralla, a three time C. diff. survivor, healthcare professional, and now dedicated to “Raising C. diff. Awareness” worldwide. Through the experiences is why we are so passionate raising C. diff. awareness. The C Diff Foundation was brought to fruition in November 2012 with a mission to educate and advocate for C. diff. infection prevention, treatment, and environmental safety worldwide. We now join the many successful hosts and programs on VoiceAmerica to deliver life-saving information through our program; “C. diff. Spores and More.”